SCHEMBL27400181

SCHEMBL27400181

CCCC(=O)OC1(c2ccc(Cl)cc2)CNC(=O)C1

nearest known ligand 0.40

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 18/20 0.40
▸ DRD4 P21917 18/20 0.40
▸ DRD3 P35462 18/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27444255 0.88 DRD2 (0.40) DRD2DRD4DRD3
SCHEMBL27405699 0.87 OPRM1 (0.43) DRD3
SCHEMBL27469099 0.86 CYP19A1 (0.38) —
SCHEMBL27401367 0.86 OPRM1 (0.37) —
SCHEMBL27403252 0.80 SLC6A2 (0.38) —
SCHEMBL28780773 0.79 IDH1 (0.34) —
SCHEMBL27406358 0.76 MEN1 (0.34) —
SCHEMBL6995994 0.71 GAA (0.41) —
SCHEMBL27896893 0.67 DRD3 (0.38) DRD2DRD4DRD3
SCHEMBL3554785 0.67 DRD3 (0.54) DRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1098264-C Substituted 4- (1H-benzimidazol-2-yl-amino) piperidines for the treatment of allergic diseases AVENTIS PHARMA INC (US) 2003-01-08 — — CN disclosed
CN-1080262-C Novel substituted 4-(1H-benzimidazol-2-YL) [1,4] diazepanes useful for the treatment of allergic diseases HOECHST MARION ROUSSEL INC (US) 2002-03-06 — — CN disclosed
CN-1207097-A Novel substituted 4- (1H-benzimidazol-2-yl) [1,4] diazepanes useful for the treatment of allergic diseases HOECHST MARION ROUSSEL INC (US) 1999-02-03 — — CN disclosed
CN-1202894-A Substituted 4-(1H-benzimidzol-2-yl-amino) piepridines useful for the treatment of allergic diseases HOECHST MARION ROUSSEL INC (US) 1998-12-23 — — CN disclosed
Send feedback